GlaxoSmithKline

• 25/05/12

  Transaction in Own Shares

• 24/05/12

  Transaction in Own Shares

• 23/05/12

  GSK amends HGS tender offer conditions

• 23/05/12

  Transaction in Own Shares

• 22/05/12

  Transaction in Own Shares

• 21/05/12

  Transaction in Own Shares

• 21/05/12

  Director/PDMR Shareholding (Replacement)

• 18/05/12

  Transaction in Own Shares

• 17/05/12

  GSK statement on tender offer to acquire HGS

• 17/05/12

  Transaction in Own Shares

• 

  09/05/12

  GlaxoSmithKline: Will realism prevail as drugs giant goes hostile with US$2.6bn HGS bid?

  Shares in GlaxoSmithKline fell in morning trade after it went hostile with its bid to acquire the American biotech Human Genome Sciences.

   

• 

  22/02/12

  Pharma sector set to outperform this year

  The pharmaceuticals sector will continue to outperform this year after a stellar 2011, according to research from Berenberg Bank

• 

  30/11/11

  Citi reveals the 'killer apps' that will unlock value in pharma sector

  Threatened by patent expiries and dwindling healthcare budgets, the pharmaceuticals industry has long been portrayed as being in terminal decline. However reports of its demise would appear to have been greatly exaggerated if the latest research from Citigroup is anything to go by.

• 

  05/06/09

  GlaxoSmithKline – A defensive remedy

  The group has around £2 billion cash in the bank and the shares are trading on an attractive forward PE of around 9x and yielding greater than 6% at current levels.

• 23/05/12

  GSK amends offer conditions in response to Human Genome Sciences poison pill

• 17/05/12

  Human Genome Sciences devises poison pill to ward off GSK bid

• 19/04/12

  GlaxoSmithKline launches US$2.6 billion hostile bid for US partner - update

• 19/04/12

  GlaxoSmithKline launches US$2.6 billion hostile bid for US partner

• 03/04/12

  GSK says diabetes treatment progressing in trials

• 22/03/12

  GlaxoSmithKline to invest £500m in UK manufacturing capacity

• 14/07/11

  GlaxoSmithKline poised to deliver a number of blockbusters, says Matrix Capital

• 18/01/11

  GlaxoSmithKline faces £2.2bn legal charge after Avandia investigation

• 01/11/10

  GlaxoSmithKline and Amicus to co-develop Amigal drug for Fabry disease

• 26/10/10

  GlaxoSmithKline to cut cost of cervical cancer vaccine in Canada by 30%

Connect with Facebook to view or add comments for this company